Merus N.V. (MRUS) Prices 4.85M Share Common Offering at $24.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Pre-Open Stock Movers 01/20: (APM) (EVLO) (NFLX) Higher; (GEVO) (HSTO) (BLRX) Lower (more...)
January 20, 2021 9:20 AM ESTPre-Open Stock Movers:
Aptorum Group Limited (NASDAQ: APM) 42.8% HIGHER; announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.
Gevo (NASDAQ: GEVO) 21.6% LOWER; announced that it has entered into definitive agreements... More
After-Hours Stock Movers 01/19: (NFLX) (CKPT) (PCAR) Higher; (HSTO) (BLRX) (ACRX) Lower (more...)
January 19, 2021 5:44 PM ESTAfter-Hours Stock Movers:
Histogen Inc. (NASDAQ: HSTO) 16.5% LOWER; announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that it has additional questions about the companys Investigational New Drug (IND) application package for the planned Phase 1/2 clinical trial of HST-003, which is intended to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.
BioLineRx Ltd. (NASDAQ:... More
Merus N.V. (MRUS) Announces $60M Proposed Public Offering of Common Shares
January 19, 2021 4:18 PM ESTMerus N.V. (Nasdaq: MRUS) (Merus, we and our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics), today announced the launch of a proposed underwritten public offering of up to $60 million of its common shares. All of the common shares are being... More
Merus N.V. (MRUS) PT Raised to $32 at Roth Capital, Following Collaboration Deal Announcement
January 19, 2021 10:56 AM ESTRoth Capital analyst Tony Butler raised the price target on Merus N.V. (NASDAQ: MRUS) to $32.00 (from $19.00) while maintaining a Buy rating.
... MoreLilly (LLY) and Merus NV (MRUS) Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021 6:35 AM ESTLoxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.
Under the terms of the agreement, Merus will lead discovery and early stage research... More
